Rinvoq™ (upadacitinib) – New drug approval
August 16, 2019 - AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX).
Download PDF
